Tradewinds Capital Management LLC held its stake in Seattle Genetics, Inc. (NASDAQ:SGEN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,344 shares of the biotechnology company’s stock at the end of the second quarter. Tradewinds Capital Management LLC’s holdings in Seattle Genetics were worth $121,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in SGEN. Vanguard Group Inc. boosted its stake in Seattle Genetics by 3.9% in the first quarter. Vanguard Group Inc. now owns 7,362,687 shares of the biotechnology company’s stock valued at $462,818,000 after buying an additional 275,044 shares during the last quarter. BlackRock Inc. boosted its stake in Seattle Genetics by 6,338.2% in the first quarter. BlackRock Inc. now owns 7,267,660 shares of the biotechnology company’s stock valued at $456,845,000 after buying an additional 7,154,776 shares during the last quarter. State Street Corp boosted its stake in Seattle Genetics by 10.9% in the first quarter. State Street Corp now owns 2,845,120 shares of the biotechnology company’s stock valued at $178,847,000 after buying an additional 279,079 shares during the last quarter. Geode Capital Management LLC boosted its stake in Seattle Genetics by 8.3% in the first quarter. Geode Capital Management LLC now owns 795,339 shares of the biotechnology company’s stock valued at $49,976,000 after buying an additional 60,696 shares during the last quarter. Finally, Pictet Asset Management Ltd. boosted its stake in Seattle Genetics by 48.4% in the second quarter. Pictet Asset Management Ltd. now owns 706,316 shares of the biotechnology company’s stock valued at $45,190,000 after buying an additional 230,492 shares during the last quarter. Hedge funds and other institutional investors own 97.91% of the company’s stock.

Shares of Seattle Genetics, Inc. (NASDAQ:SGEN) opened at 46.20 on Friday. The company has a 50-day moving average price of $52.63 and a 200-day moving average price of $61.26. The firm’s market capitalization is $6.61 billion. Seattle Genetics, Inc. has a 12-month low of $42.58 and a 12-month high of $75.36.

Seattle Genetics (NASDAQ:SGEN) last posted its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.03. The business had revenue of $108.20 million during the quarter, compared to the consensus estimate of $105.92 million. Seattle Genetics had a negative net margin of 47.38% and a negative return on equity of 32.87%. The firm’s revenue for the quarter was up 13.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.23) earnings per share. Equities analysts predict that Seattle Genetics, Inc. will post ($1.70) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Tradewinds Capital Management LLC Has $121,000 Position in Seattle Genetics, Inc. (SGEN)” was reported by Daily Political and is owned by of Daily Political. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/08/11/tradewinds-capital-management-llc-has-121000-position-in-seattle-genetics-inc-sgen.html.

Several equities research analysts have weighed in on SGEN shares. J P Morgan Chase & Co restated a “hold” rating and set a $58.00 target price on shares of Seattle Genetics in a research note on Tuesday, June 13th. Cantor Fitzgerald restated a “hold” rating and set a $43.00 target price on shares of Seattle Genetics in a research note on Monday, June 26th. Piper Jaffray Companies restated a “neutral” rating and set a $48.00 target price on shares of Seattle Genetics in a research note on Tuesday, June 27th. Cowen and Company set a $61.00 target price on Seattle Genetics and gave the stock a “hold” rating in a research note on Tuesday, June 6th. Finally, Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Seattle Genetics in a research note on Thursday, June 15th. Five research analysts have rated the stock with a sell rating, ten have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $62.07.

In other Seattle Genetics news, CEO Clay B. Siegall sold 10,423 shares of the business’s stock in a transaction on Wednesday, July 5th. The shares were sold at an average price of $51.98, for a total value of $541,787.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CMO Jonathan G. Drachman sold 10,000 shares of the business’s stock in a transaction on Thursday, July 27th. The stock was sold at an average price of $54.54, for a total transaction of $545,400.00. The disclosure for this sale can be found here. Insiders sold 57,259 shares of company stock valued at $3,211,411 over the last three months. 33.30% of the stock is currently owned by insiders.

Seattle Genetics Company Profile

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Want to see what other hedge funds are holding SGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Seattle Genetics, Inc. (NASDAQ:SGEN).

Institutional Ownership by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.